Tags

Type your tag names separated by a space and hit enter

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
Mov Disord. 1993 Apr; 8(2):165-70.MD

Abstract

Subcutaneous apomorphine, administered by continuous waking-day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on-off fluctuations for 1-5 years. A mean reduction in daily off period time of approximately 50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long-term follow-up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on-phase dyskinesias and postural instability marred the long-term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late-stage Parkinson's disease and should certainly be considered before experimental implantation procedures.

Authors+Show Affiliations

Department of Neurology, Middlesex Hospital, London, England.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8474483

Citation

Hughes, A J., et al. "Subcutaneous Apomorphine in Parkinson's Disease: Response to Chronic Administration for Up to Five Years." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 8, no. 2, 1993, pp. 165-70.
Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993;8(2):165-70.
Hughes, A. J., Bishop, S., Kleedorfer, B., Turjanski, N., Fernandez, W., Lees, A. J., & Stern, G. M. (1993). Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Movement Disorders : Official Journal of the Movement Disorder Society, 8(2), 165-70.
Hughes AJ, et al. Subcutaneous Apomorphine in Parkinson's Disease: Response to Chronic Administration for Up to Five Years. Mov Disord. 1993;8(2):165-70. PubMed PMID: 8474483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. AU - Hughes,A J, AU - Bishop,S, AU - Kleedorfer,B, AU - Turjanski,N, AU - Fernandez,W, AU - Lees,A J, AU - Stern,G M, PY - 1993/4/1/pubmed PY - 1993/4/1/medline PY - 1993/4/1/entrez SP - 165 EP - 70 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 8 IS - 2 N2 - Subcutaneous apomorphine, administered by continuous waking-day infusion with boluses, or by repeated intermittent injection, was given to 71 parkinsonian patients with severe refractory levodopa related on-off fluctuations for 1-5 years. A mean reduction in daily off period time of approximately 50% was maintained, and the incidence of neuropsychiatric toxicity remained low on long-term follow-up. No clinically significant tolerance or loss of therapeutic effect was seen, although increasingly severe on-phase dyskinesias and postural instability marred the long-term therapeutic response in many patients. Despite these drawbacks, apomorphine, when combined with the peripheral dopamine receptor agonist domperidone, represents a significant therapeutic advance in the management of late-stage Parkinson's disease and should certainly be considered before experimental implantation procedures. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/8474483/Subcutaneous_apomorphine_in_Parkinson's_disease:_response_to_chronic_administration_for_up_to_five_years_ L2 - https://doi.org/10.1002/mds.870080208 DB - PRIME DP - Unbound Medicine ER -